The aim of the project, following a specific strategy of rational and scientifically substantiated approach, is to develop an innovative molecule for the targeted treatment of hormone-dependent cancer. The product will comprise a peptide analogue of GnRH (Gonadotropin Releasing Hormone ή LHRH, Luteinizing Hormone-Releasing Hormone) conjugated with a cytostatic agent for the selective destruction of GnRH receptor-bearing cancer cells. The goal is to reduce the side effects of chemotherapy and achieve better efficacy.
Additional objectives of the project are:
- i) The connection of research and innovation with entrepreneurship;
- (ii) The emergence and confirmation of a new and innovative, targeted cancer treatment;
- (iii) The acquisition of new knowledge and skills that will be created by the collaboration of Excelya (formerly ZeinCRO) with research organizations, with the prospect of creating an improved anti-cancer molecule and promoting it in the “drug market” and
- (iv) Creating a business plan from the company (Excelya, formerly ZeinCRO) for product development .